We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Biomimetic Nanoparticles Prove Effective for Biotherapeutic Drug Transport

By LabMedica International staff writers
Posted on 19 Mar 2018
Print article
Image: The process of extracting proteolipid material, protein enrichment, and vesicular formulation of leukosomes (Photo courtesy of the Houston Methodist Research Institute).
Image: The process of extracting proteolipid material, protein enrichment, and vesicular formulation of leukosomes (Photo courtesy of the Houston Methodist Research Institute).
Nanoparticles coated with proteins from immune system leukocytes were shown to provide an effective transport and delivery system for biotherapeutic drugs.

Though the advantages of transferring biological features from cells to synthetic nanoparticles for drug delivery purposes have recently been reported, a standardizable, batch-to-batch consistent, scalable, and high-throughput assembly method is required to further develop these platforms.

In a paper published in the March 7, 2018, online edition of the journal Advanced Materials, investigators at the Houston Methodist Research Institute (TX, USA) described the preparation of biomimetic "leukosome" nanoparticles that incorporated membrane proteins within the particles' bilayer. The nanoparticles were fabricated using a microfluidic-based platform.

Evaluation of the NA-Leuko nanoparticles revealed that they showed extended shelf life and retention of the biological functions of donor cells (i.e., macrophage avoidance and targeting of inflamed vasculature).

"The body is so smart in the ways it defends itself. The immune system will eventually recognize nanoparticles no matter how well you make them," said senior author Dr. Ennio Tasciotti, professor of biomimetic medicine at the Houston Methodist Research Institute. "In my lab, we make nanoparticles out of the cell membrane of the very same immune cells that patrol the blood stream. When we put these biomimetic, or bioinspired, nanoparticles back in the body, the immune cells do not recognize them as something different, as they are made of their same building blocks, so there is no adverse response."

"While our lab will remain fully devoted to this line of research, if somebody else develops some solutions using our protocols that are useful in clinical care, it's still a good outcome," said Dr. Tasciotti. "After all, the ultimate reason why we are in translational science is for the benefit of the patients."

Related Links:
Houston Methodist Research Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.